Kura Oncology Shares Are Trading Higher After the Company Announced That It Dosed Its First Patient in Its Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Kura Oncology宣佈在 KO-2806 Plus 卡博贊替尼治療腎細胞癌的試驗中爲首位患者注射劑量後,該公司股價走高
Kura Oncology Shares Are Trading Higher After the Company Announced That It Dosed Its First Patient in Its Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Kura Oncology宣佈在 KO-2806 Plus 卡博贊替尼治療腎細胞癌的試驗中爲首位患者注射劑量後,該公司股價走高
使用瀏覽器的分享功能,分享給你的好友吧